03/22/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/22/2024 4:45 PM | CRISPR Therapeutics (Issuer) Prasad Raju (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/22/2024 4:45 PM | CRISPR Therapeutics (Issuer) KASINGER JAMES R. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/22/2024 3:02 PM | CRISPR Therapeutics (Subject) Morrow Phuong Khanh (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/18/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/18/2024 4:45 PM | CRISPR Therapeutics (Issuer) Prasad Raju (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/15/2024 3:43 PM | CRISPR Therapeutics (Subject) Kulkarni Samarth (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
|
03/12/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/12/2024 4:45 PM | CRISPR Therapeutics (Issuer) KASINGER JAMES R. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/27/2024 5:39 PM | CRISPR Therapeutics (Issuer) George Simeon (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/21/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/21/2024 4:45 PM | CRISPR Therapeutics (Issuer) KASINGER JAMES R. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/21/2024 6:45 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/21/2024 6:50 AM | CRISPR Therapeutics (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/16/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/15/2024 3:30 PM | CRISPR Therapeutics (Subject) Kulkarni Samarth (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
02/13/2024 4:22 PM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/13/2024 7:44 AM | CRISPR Therapeutics (Filer)
| Form 424B5 | |
02/13/2024 5:30 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/13/2024 5:30 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/12/2024 5:22 PM | CRISPR Therapeutics (Subject) Nikko Asset Management Americas, Inc. (Filed by)
| Form SC 13G/A | |
02/05/2024 5:08 AM | CRISPR Therapeutics (Subject) Sumitomo Mitsui Trust Holdings, Inc. (Filed by)
| Form SC 13G/A | |
01/31/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2024 3:00 PM | ARK Investment Management LLC (Filed by) CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
01/18/2024 4:45 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/10/2024 10:36 AM | ARK Investment Management LLC (Filed by) CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
12/15/2023 7:58 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/13/2023 8:22 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/08/2023 12:16 PM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/16/2023 6:21 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/06/2023 3:42 PM | CRISPR Therapeutics (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
11/06/2023 3:33 PM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/17/2023 4:52 PM | CRISPR Therapeutics (Issuer) Morrow Phuong Khanh (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/17/2023 4:52 PM | CRISPR Therapeutics (Issuer) Prasad Raju (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/17/2023 4:48 PM | CRISPR Therapeutics (Issuer) KASINGER JAMES R. (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/17/2023 4:51 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
09/07/2023 7:39 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/09/2023 4:33 PM | CRISPR Therapeutics (Issuer) Fardis Maria (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/09/2023 4:34 PM | CRISPR Therapeutics (Issuer) Fleming Harold Edward (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/09/2023 4:34 PM | CRISPR Therapeutics (Issuer) Greene John (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/09/2023 4:36 PM | CRISPR Therapeutics (Issuer) High Katherine A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Buy Friday, Sell Monday, No Exceptions (Ad) Every week traders grind it out Monday through Friday…
But neglect trading Friday to Monday…
Or… “over the weekend”
As one professional trader explains, trading over the weekend is one of the most forgiving strategies you can use today.
It allows him to sidestep a lot of the midweek volatility.
Yet, gives him the opportunity to target some of the markets biggest stock moves.
Just recently, he posted a trade on Nordstrom…
The trade was published at 3pm on a Friday afternoon and by Monday morning the trade more than doubled. And for the first time in 2024, he’s sharing his strategy for free. |
06/09/2023 4:36 PM | CRISPR Therapeutics (Issuer) Treco Douglas A (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/09/2023 4:48 PM | Behbahani Ali (Reporting) CRISPR Therapeutics (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/09/2023 4:56 PM | CRISPR Therapeutics (Issuer) George Simeon (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/09/2023 6:07 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/01/2023 4:44 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/30/2023 3:38 PM | CRISPR Therapeutics (Subject) Kulkarni Samarth (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/25/2023 4:35 PM | CRISPR Therapeutics (Issuer) Morrow Phuong Khanh (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
05/10/2023 2:23 PM | CRISPR Therapeutics (Subject) Smith Brendan (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/27/2023 4:37 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/26/2023 3:38 PM | CRISPR Therapeutics (Filer)
| Form ARS | |
04/25/2023 3:28 PM | CRISPR Therapeutics (Subject) Kulkarni Samarth (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
04/10/2023 8:17 PM | ARK Investment Management LLC (Filed by) CRISPR Therapeutics (Subject)
| Form SC 13G/A | |
04/10/2023 3:40 PM | CRISPR Therapeutics (Filer)
| Form PRE 14A | |
04/03/2023 7:10 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/31/2023 4:49 PM | CRISPR Therapeutics (Issuer) Kulkarni Samarth (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/29/2023 7:08 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/27/2023 7:08 AM | CRISPR Therapeutics (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |